Improving the validity and translation of preclinical research

Judith A. Pratt, Emma S. J. Robinson, Cathy Fernandes, David Heal, S Clare Stanford

Research output: Contribution to journalEditorialpeer-review

1 Citation (Scopus)
19 Downloads (Pure)

Abstract

The Oct 2021 edition of J. Psychopharmacology focussed on the contemporary topic of translational psychopharmacology. Translational research is critical for the development of early interventions and improved therapeutics for mental health conditions. In this respect, the continual updating of information gained from reciprocal forward (preclinical) and reverse (clinical) translational approaches is necessary. Despite the enthusiasm for translational psychopharmacology in the preclinical research community, there are many challenges if we are to achieve the crucial goal of developing therapies with superior efficacy and tolerability over current drugs for neuropsychiatric conditions. At a recent meeting of a preclinical subpanel of the J. Psychopharmacology editorial board, members debated opportunities to improve the validity and translation of preclinical research models. A particular focus being the importance of understanding the clinical relevance of a model and its readouts and how well the mechanisms associated with those readouts and arising novel drug targets translate to the clinic. Importantly, consideration was given to moving away from pharmacological models towards the development of approaches which recapitulate more clinically relevant readouts. Some key points are summarised below.
Original languageEnglish
Pages (from-to)779-780
Number of pages2
JournalJournal of Psychopharmacology
Volume36
Issue number7
Early online date10 Jun 2022
DOIs
Publication statusPublished - Jul 2022

Keywords

  • editorial
  • psychopharmacology
  • preclinical research

Fingerprint

Dive into the research topics of 'Improving the validity and translation of preclinical research'. Together they form a unique fingerprint.

Cite this